全文获取类型
收费全文 | 927篇 |
免费 | 65篇 |
国内免费 | 1篇 |
学科分类
医药卫生 | 993篇 |
出版年
2023年 | 5篇 |
2021年 | 10篇 |
2020年 | 10篇 |
2019年 | 16篇 |
2018年 | 14篇 |
2017年 | 10篇 |
2016年 | 24篇 |
2015年 | 18篇 |
2014年 | 17篇 |
2013年 | 27篇 |
2012年 | 46篇 |
2011年 | 57篇 |
2010年 | 23篇 |
2009年 | 24篇 |
2008年 | 52篇 |
2007年 | 73篇 |
2006年 | 63篇 |
2005年 | 51篇 |
2004年 | 65篇 |
2003年 | 54篇 |
2002年 | 52篇 |
2001年 | 38篇 |
2000年 | 30篇 |
1999年 | 23篇 |
1998年 | 10篇 |
1997年 | 6篇 |
1996年 | 8篇 |
1995年 | 5篇 |
1994年 | 7篇 |
1993年 | 4篇 |
1992年 | 7篇 |
1991年 | 11篇 |
1990年 | 8篇 |
1989年 | 8篇 |
1988年 | 12篇 |
1987年 | 7篇 |
1986年 | 9篇 |
1985年 | 10篇 |
1984年 | 10篇 |
1983年 | 11篇 |
1982年 | 5篇 |
1979年 | 6篇 |
1977年 | 4篇 |
1974年 | 7篇 |
1973年 | 4篇 |
1972年 | 5篇 |
1971年 | 4篇 |
1970年 | 4篇 |
1968年 | 4篇 |
1966年 | 2篇 |
排序方式: 共有993条查询结果,搜索用时 15 毫秒
1.
2.
Fabio Paglialonga Claus Peter Schmitt Rukshana Shroff Karel Vondrak Christoph Aufricht Alan Rees Watson Gema Ariceta Michael Fischbach Gunter Klaus Tuula Holtta Sevcan A. Bakkaloglu Alexandra Zurowska Augustina Jankauskiene Johan Vande Walle Betti Schaefer Elizabeth Wright Roy Connell Alberto Edefonti 《Pediatric nephrology (Berlin, Germany)》2015,30(1):103-111
3.
4.
Stephanie Dufek Tuula Holtta Michel Fischbach Gema Ariceta Augustina Jankauskiene Rimante Cerkauskiene Claus Peter Schmitt Betti Schaefer Christoph Aufricht Elizabeth Wright Constantinos J. Stefanidis Mesiha Ekim Sevcan Bakkaloglu Günter Klaus Aleksandra Zurowska Karel Vondrak Johan Vande Walle Alberto Edefonti Rukshana Shroff 《Pediatric nephrology (Berlin, Germany)》2015,30(11):2021-2027
5.
Pauline De Bruyne Ann De Guchtenaere Charlotte Van Herzeele Ann Raes Jo Dehoorne Piet Hoebeke Erik Van Laecke Johan Vande Walle 《European journal of pediatrics》2014,173(2):223-228
Desmopressin 120 μg oral lyophilisate and 200 μg tablet are considered bioequivalent, based on extrapolation of studies in a limited number of adults and on one dose-finding study of desmopressin oral lyophilisate in children. However, no comparative pharmacokinetic study in children was executed confirming this statement. No data are available on the influence of food intake on the bioavailability of desmopressin tablet in a pediatric setting, although studies in adults have documented that food intake results in a significantly lower desmopressin plasma concentration. In this study, we analyzed plasma concentrations of desmopressin oral lyophilisate and tablet with concomitant food intake. Twenty-three children with monosymptomatic nocturnal enuresis (mean age, 12.7 years) were recruited. Two tests were performed on two separate days in identical conditions with a standardized food and fluid intake. Desmopressin was administered as desmopressin tablet or desmopressin oral lyophilisate immediately after a meal. Desmopressin plasma concentration was measured at 1 h, 2 h, and 6 h postdosing. No significant difference in plasma concentration of 120 μg desmopressin oral lyophilisate and 200 μg tablet was demonstrated, even with concomitant food intake. A significant difference in variability was found, identifying a smaller variance for desmopressin oral lyophilisate plasma concentrations at all time points. This study demonstrates comparable plasma levels for desmopressin oral lyophilisate, despite the lower dose. The dosage for desmopressin oral lyophilisate is more predictable due to the significantly smaller variance. Therefore, desmopressin oral lyophilisate seems more suitable, especially in the younger age group for which time interval between dinner and drug administration is limited. 相似文献
6.
7.
8.
J Williams DCH FRCP KA Richards MSc UK Study Group 《International journal of clinical practice》1997,51(3):147-153
A total of 323 children aged 4-11 years who were receiving, or had symptoms indicating a clinical requirement for, inhaled corticosteroid at a daily dose of 400 μg budesonide (BUD) or beclomethasone dipropionate (BDP), or 200 μg fluticasone propionate (FP), were randomised into this multicentre, open-label, parallel group study. Patients received either FP 100 μg b.d. administered via the Accuhaler/Diskus inhaler (n=159) or BUD 200 μg b.d. administered via a Turbohaler inhaler (n=164) for four weeks and recorded daily their morning and evening peak expiratory flow (PEF), asthma symptoms and use of relief medication. Device handling was assessed by a questionnaire, with responses recorded on three- or five-point ordinal scales. The primary efficacy parameter was mean percent predicted morning PEF. The device handling results showed the Accuhaler/Diskus inhaler was rated more favourably than the Turbohaler inhaler in terms of ease of correct inhaler use, ease of telling how many doses were left, ease of knowing whether a dose had been inhaled and overall liking of the device. More patients in the Accuhaler/Diskus group (85%) than in the Turbohaler group (58%) said they would be happy to receive the same device again, while 8% and 25% respectively said they would not be happy to be given it again. In addition, the change from baseline to week 4 of treatment in mean percent predicted morning PEF was greater in the FP Accuhaler/Diskus group, indicating that FP 200 μg daily via Accuhaler/Diskus inhaler is at least as clinically effective as BUD 400 μg daily via the Turbohaler inhaler. 相似文献
9.
Van de Walle I De Smet G Gärtner M De Smedt M Waegemans E Vandekerckhove B Leclercq G Plum J Aster JC Bernstein ID Guidos CJ Kyewski B Taghon T 《Blood》2011,117(17):4449-4459
Notch signaling critically mediates various hematopoietic lineage decisions and is induced in mammals by Notch ligands that are classified into 2 families, Delta-like (Delta-like-1, -3 and -4) and Jagged (Jagged1 and Jagged2), based on structural homology with both Drosophila ligands Delta and Serrate, respectively. Because the functional differences between mammalian Notch ligands were still unclear, we have investigated their influence on early human hematopoiesis and show that Jagged2 affects hematopoietic lineage decisions very similarly as Delta-like-1 and -4, but very different from Jagged1. OP9 coculture experiments revealed that Jagged2, like Delta-like ligands, induces T-lineage differentiation and inhibits B-cell and myeloid development. However, dose-dependent Notch activation studies, gene expression analysis, and promoter activation assays indicated that Jagged2 is a weaker Notch1-activator compared with the Delta-like ligands, revealing a Notch1 specific signal strength hierarchy for mammalian Notch ligands. Strikingly, Lunatic-Fringe- mediated glycosylation of Notch1 potentiated Notch signaling through Delta-like ligands and also Jagged2, in contrast to Jagged1. Thus, our results reveal a unique role for Jagged1 in preventing the induction of T-lineage differentiation in hematopoietic stem cells and show an unexpected functional similarity between Jagged2 and the Delta-like ligands. 相似文献
10.
Mead GM Barrans SL Qian W Walewski J Radford JA Wolf M Clawson SM Stenning SP Yule CL Jack AS;UK National Cancer Research Institute Lymphoma Clinical Studies Group;Australasian Leukaemia Lymphoma Group 《Blood》2008,112(6):2248-2260
This prospective study aimed to develop reproducible diagnostic criteria for sporadic Burkitt lymphoma (BL), applicable to routine practice, and to evaluate the efficacy of dose-modified (dm) CODOX-M/IVAC in patients diagnosed using these criteria. The study was open to patients with an aggressive B-cell lymphoma with an MKI67 fraction approaching 100%. Immunophenotype and fluorescent in situ hybridization (FISH) were used to separate BL from other aggressive B-cell lymphomas. BL was characterized by the presence of a cMYC rearrangement as a sole cytogenetic abnormality occurring in patients with a germinal center phenotype with absence of BCL-2 expression and abnormal TP53 expression. A total of 128 patients were eligible for the study, of whom 58 were considered to have BL and 70 to have diffuse large B-cell lymphoma (DLBCL). There were 110 clinically fit patients who received dmCODOX-M (methotrexate, dose 3 g/m(2)) with or without IVAC according to risk group. The 2-year progression-free survival was 64% (95% confidence interval [CI] 51%-77%) for BL, 55% (95% CI 42%-66%) for DLBCL, 85% (95% CI 73%-97%) for low risk, and 49% (95% CI 38%-60%) for high-risk patients. The observed differences in outcome and other clinical features validate the proposed diagnostic criteria. Compared with the previous trial LY06 with full-dose methotrexate (6.7 g/m(2)), there was a reduction in toxicity with comparable outcomes. This study was registered at www.clinicaltrials.gov as NCT00040690. 相似文献